May 2023
Joint Global Coordinator & Joint Bookrunner
€25.0 million
Accelerated Bookbuild Offering
Vivoryon Therapeutics
Joint Global Coordinator & Joint Bookrunner
Van Lanschot Kempen acted as Joint Global Coordinator & Joint Bookrunner in the €25.0 million Capital Increase by Vivoryon Therapeutics
Transaction highlights
- €25.0 million Capital Increase via accelerated bookbuild to existing and new international institutional investors corresponding to 7.4% of the company’s outstanding share capital
- The price of €14.00 per new share represented a limited discount of 3.4% compared to the last closing price before transaction announcement amid challenging market circumstances
- The Capital Increase launched following a supportive market sounding exercise leading up to the orderbook being significantly oversubscribed
- Vivoryon Therapeutics intends to use the proceeds to accelerate ongoing clinical development, conduct discussions with the FDA and to further explore and leverage the full potential of its lead candidate in the evolving Alzheimer’s disease field
- The funds are expected to extend Vivoryon Therapeutics' cash runway into the second half of 2024
- Following previous involvement with Vivoryon Therapeutics, including the IPO on Euronext Amsterdam in 2014 and several follow-on Capital Increases, we are proud to have assisted this repeat client raising capital for the fourth time
Company description
Vivoryon Therapeutics is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins for patients living with severe diseases. The company focuses primarily on development of therapeutic products for the treatment of AD, cancer, inflammation, and fibrosis. Its lead product candidate, Varoglutamstat, is in Phase II clinical development for AD.
Vivoryon Therapeutics is listed on the regulated market of Euronext Amsterdam (Ticker: VVY) and headquartered in Halle, Germany.
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
Vivoryon Therapeutics is listed on the regulated market of Euronext Amsterdam (Ticker: VVY) and headquartered in Halle, Germany.
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Global Coordinator & Joint Bookrunner in the €15.8 million Capital Increase by Sequana Medical
- Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
- Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
- Lead Manager in the USD 250 million US Public Offering by CureVac
- Sole Financial Adviser to GenSight Biologics in securing a €12.0 million credit facility from Heights Capital Management
- Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
- Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80m PIPE
- Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
- Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
- Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank (EIB)
- Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild offering of Xbrane Biopharma
- Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
- Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
- Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
- Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
- Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue by Abliva
- Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma
- Financial adviser in the spin-out and capital increase of InnoSIGN